Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.72% | 20.22% | 19.57% | 6.48% | 6.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.00% | 18.55% | 10.71% | 5.85% | 17.04% |
| Operating Income | -38.00% | -18.55% | -10.71% | -5.85% | -17.04% |
| Income Before Tax | -45.62% | -23.23% | -10.55% | -3.98% | -12.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.62% | -23.23% | -10.55% | -3.98% | -12.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.62% | -23.23% | -10.55% | -3.98% | -12.67% |
| EBIT | -38.00% | -18.55% | -10.71% | -5.85% | -17.04% |
| EBITDA | -38.39% | -18.50% | -10.50% | -5.46% | -17.27% |
| EPS Basic | -17.96% | 6.29% | 21.47% | 42.80% | 48.68% |
| Normalized Basic EPS | -17.23% | 7.45% | 21.25% | 42.80% | 48.82% |
| EPS Diluted | -17.96% | 6.29% | 21.47% | 42.80% | 48.68% |
| Normalized Diluted EPS | -17.23% | 7.45% | 21.25% | 42.80% | 48.82% |
| Average Basic Shares Outstanding | 19.92% | 29.70% | 39.80% | 58.29% | 86.22% |
| Average Diluted Shares Outstanding | 19.92% | 29.70% | 39.80% | 58.29% | 86.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |